Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study

BACKGROUND: By July 14, 2021, 81·3 % of adults (aged ≥18 years) in Chile had received a first SARS-CoV-2 vaccine and 72·3% had received a second SARS-CoV-2 vaccine, with the majority of people given Sinovac's inactivated CoronaVac vaccine (75·3% of vaccines dispensed) or Pfizer–BioNTech's...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauré, Denis, O'Ryan, Miguel, Torres, Juan Pablo, Zuniga, Marcela, Santelices, Emilio, Basso, Leonardo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428469/
https://www.ncbi.nlm.nih.gov/pubmed/34509185
http://dx.doi.org/10.1016/S1473-3099(21)00479-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428469/
https://www.ncbi.nlm.nih.gov/pubmed/34509185
http://dx.doi.org/10.1016/S1473-3099(21)00479-5

Ejemplares similares